Hillchol
Commercial- Indications
- Cholera
Company intelligence / Profile preview
Sapigen Biologix
Hyderabad, Telangana, Indiasapigen.com ↗
- Ownership
- Private
- Employees
- ~1500
- Development stage
- Commercial
01
Overview
Preparing to start commercial production of vaccines including RTS,S malaria vaccine by May 2025. The company aims to produce around 15 million doses per annum of the malaria vaccine by the end of April 2025[5].
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- VaccinesBiologicalsBio-therapeuticsRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Technology Development Board of the Ministry of Science and Technology
Beyond the preview
Go deeper on Sapigen Biologix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sapigen Biologix.